These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34258319)

  • 1. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients.
    Piccicacco N; Zeitler K; Montero J; Kumar A; Lakshmi S; Kim K; Wein D; Vasey T; Vasey M; Oxner A
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab292. PubMed ID: 34258319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
    Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
    Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
    Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E;
    Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Monoclonal Antibodies in Preventing Hospitalizations, Emergency Department Visits, and Mortality in High-Risk COVID-19 Patients.
    Milam AN; Doan DT; Childress DT; Durham SH
    J Pharm Technol; 2022 Jun; 38(3):169-173. PubMed ID: 35600282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.
    McCreary EK; Bariola JR; Wadas RJ; Shovel JA; Wisniewski MK; Adam M; Albin D; Minnier T; Schmidhofer M; Meyers R; Marroquin OC; Collins K; Garrard W; Berry LR; Berry S; Crawford AM; McGlothlin A; Linstrum K; Nakayama A; Montgomery SK; Snyder GM; Yealy DM; Angus DC; Kip PL; Seymour CW; Huang DT; Kip KE
    JAMA Netw Open; 2022 Apr; 5(4):e226920. PubMed ID: 35412625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison of the Adverse Effects and Utility of Different Monoclonal Antibodies for SARS-CoV-2: A Retrospective Cohort Study.
    Knopp BW; Weiss HZ; Fahmy S; Goldstein E; Parmar J
    Cureus; 2023 Aug; 15(8):e43094. PubMed ID: 37680398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy : A Cohort Study.
    McCreary EK; Lemon L; Megli C; Oakes A; Seymour CW;
    Ann Intern Med; 2022 Dec; 175(12):1707-1715. PubMed ID: 36375150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of severe acute respiratory syndrome coronavirus 2 monoclonal antibodies in high-risk solid organ transplant recipients across three major coronavirus disease 2019 variant waves.
    Zeitler K; Piccicacco N; O'Neal M; Montero J; Myers A; Strebig D; Nestler S; Anger LB; Kim K
    Transpl Infect Dis; 2023 Aug; 25(4):e14095. PubMed ID: 37378536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Casirivimab/imdevimab treatment for outpatient COVID-19 during a SARS-CoV-2 B1.617.2 (Delta) surge at a community hospital.
    Keshishian E; Kuge E; Memmott J; Hasenbalg P; Belford N; Matlock A; Schritter S; Agbayani G; Dietrich T; Santarelli A; Ashurst J
    J Osteopath Med; 2022 Dec; 122(12):635-640. PubMed ID: 36123325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital.
    Farcy DA; Dalley MT; Miro G; Swalley P; Sherman D; Nash J; Jodoin K; Cubeddu LX; Zitek T; Goldszer R
    J Emerg Med; 2022 Jan; 62(1):83-91. PubMed ID: 34489146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial.
    McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Nakayama A; Zapf RL; Kip PL; Seymour CW; Huang DT
    Contemp Clin Trials; 2022 Aug; 119():106822. PubMed ID: 35697146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Propensity-Matched Cohort Assessing Impact of a Neutralizing Monoclonal Antibody in Mild-to-Moderate Coronavirus Disease 2019.
    Abbas M; Farhat N; Hammoud Z; Dickey C; Shuayto A; Chen NW; Hsaiky LM; Sims M; Sengstock D; Schramski J; Shamoon Z
    J Intensive Care Med; 2023 Jun; 38(6):511-518. PubMed ID: 36775970
    [No Abstract]   [Full Text] [Related]  

  • 13. Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19.
    Webb BJ; Buckel W; Vento T; Butler AM; Grisel N; Brown SM; Peltan ID; Spivak ES; Shah M; Sakata T; Wallin A; Stenehjem E; Poulsen G; Bledsoe J
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab331. PubMed ID: 34327256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort.
    Nichols CN; Lustberg M; Sobhanie MME; Niermann LJ; Gordon M; Kman N; Parsons J; Conroy M; Dick M; Allen J; Reed E; Lehman J; Malvestutto C
    Antivir Ther; 2024 Aug; 29(4):13596535241264694. PubMed ID: 39066463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal Antibody Infusions for Outpatient Management of Mild-Moderate COVID-19.
    Knox HB; Dykes LA; Scott LA; Presley BC; Lambert LC
    Ann Pharmacother; 2024 Oct; 58(10):985-993. PubMed ID: 38288555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world evaluation of the impact of two anti-SARS-CoV-2 monoclonal antibody regimens on COVID-19 hospitalizations in older adults.
    Sobolewski KA; Smoke SM; Brophy A; Vassallo AV; Chen B; Hilden P; Patterson R; Pittiglio M; Raja K; Handler E; Freer C
    J Med Virol; 2022 Jun; 94(6):2493-2499. PubMed ID: 35199356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world Assessment of 2879 COVID-19 Patients Treated With Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study.
    Cooper MH; Christensen PA; Salazar E; Perez KK; Graviss EA; Nguyen D; Musser JM; Huang HJ; Liebl MG
    Open Forum Infect Dis; 2021 Nov; 8(11):ofab512. PubMed ID: 35559124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    Bariola JR; McCreary EK; Wadas RJ; Kip KE; Marroquin OC; Minnier T; Koscumb S; Collins K; Schmidhofer M; Shovel JA; Wisniewski MK; Sullivan C; Yealy DM; Nace DA; Huang DT; Haidar G; Khadem T; Linstrum K; Seymour CW; Montgomery SK; Angus DC; Snyder GM
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab254. PubMed ID: 34250192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern.
    Falcone M; Tiseo G; Valoriani B; Barbieri C; Occhineri S; Mazzetti P; Vatteroni ML; Suardi LR; Riccardi N; Pistello M; Tacconi D; Menichetti F
    Infect Dis Ther; 2021 Dec; 10(4):2479-2488. PubMed ID: 34435337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients.
    Wang AX; Busque S; Kuo J; Singh U; Röeltgen K; Pinsky BA; Chertow GM; Scandling JD; Lenihan CR
    Kidney360; 2022 Jan; 3(1):133-143. PubMed ID: 35368573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.